Stocks to watch: RPRX, DDS and DSCI

During the first week of January, Repros Therapeutics Inc. ( NASDAQ: RPRX ) received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal in men with secondary hypogonadism. Last month, Repros reported its plans to license its testosterone treatment by the end of 2011 and expects to raise cash through a share sale by March 2011. Repros shares have a 52-week range of $1.11-$4.88. The stock is currently trading above its 50-day and 200-daymoving averages. Repros shares gained 2.07% in the last three trading sessions. The Woodlands, Texas-based Reprose is a development-stage biopharmaceutical company, engaged in the development of oral small molecule drugs for unmet medical needs. Dillard’s Inc. ( NYSE: DDS ) shares rallied on Thursday after the company said that it form a real estate investment trust. Last December, Dillard’s declared a cash dividend of $0.04 per share on the Class A and Class B Common Stock of the Company payable February 1, 2011. Dillard’s announced its plans to repurchase up to $250 million of its Class A Common Stock through open market or through privately negotiated transactions. Dillard's is a    Little Rock, Arkansas-based retailer, engaged in apparel and home furnishing retail business. Derma Sciences Inc. ( NASDAQ: DSCI ), last July, Derma Sciences submitted a 510(k) application to the U.S. Food and Drug Administration for MEDIHONEY Gel Wound & Burn Dressing. It also announced that the U.S. Patent and Trademark Office has issued patent No. 7,714,183 related to the Company`s MEDIHONEY Calcium Alginate Dressing. Derma Sciences shares have a 52-week range of $4.40-$9. The stock is currently trading above its 50-day and 200-day moving averages. In the last one year, Derma shares climbed 564.47%. Derma is a Princeton, New Jersey-based specialty medical device/pharmaceutical company, focusing primarily on wound care. This corporate profile is provided for information purposes only and should not be used as the basis for any investment decision. We are neither licensed nor qualified to provide investment advice. We were not paid, nor do we hold a position in these stocks. We reserve the right to buy or sell any stock mentioned in this report at any time after this post.
Negocioenlinea
tdp2664Penny Stock Live